COMPLEX OF UREA DERIVATIVE WITH Tc RADIONUCLIDE LABEL FOR DIAGNOSIS OF TUMORS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, AND METHOD FOR PRODUCTION THEREOF Russian patent published in 2024 - IPC A61K51/04 A61K51/08 A61K103/10 C07K7/06 C07F13/00 

FIELD: organic chemistry; medicine; oncology; pharmacology.

SUBSTANCE: invention relates to a complex of a urea derivative with ^99mTc radionuclide label for the diagnosis of tumors expressing a prostate-specific membrane antigen, ^99mTc-(((1S)-5-((2S)-2-((2S)-2-(8-((2S)-2-acetamido-6-(2-(4-carboxy-2-(4-carboxy-2-(4-carboxy-2-(2-mercaptoacetamido)butanamido)butanamido)butanamido)acetamido)hexanamido)octanamido)-3-(4-hydroxyphenyl)propanamido)-3-(naphthalen-2-yl)propane-amido)-1-carboxypentyl)carbamoyl)-L-glutamic acid, presented by the structural formula given below. Also disclosed is a method of producing said complex of a derivative of urea with ^99mTc radionuclide label.

EFFECT: wider range of complexes of urea derivatives with ^99mTc radionuclide label for the diagnosis of tumors expressing a prostate-specific membrane antigen, with simultaneous increase in specific tumor uptake to (30±4) % and tumor:blood ratio to (38±14).

2 cl, 2 dwg, 1 tbl, 12 ex